AGIOS PHARMACEUTICALS, INC.·4

Feb 17, 4:14 PM ET

Miles Darrin 4

4 · AGIOS PHARMACEUTICALS, INC. · Filed Feb 17, 2021

Insider Transaction Report

Form 4
Period: 2021-02-14
Miles Darrin
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common stock

    2021-02-14+8,66614,541 total
  • Exercise/Conversion

    Common stock

    2021-02-16+92215,463 total
  • Tax Payment

    Common stock

    2021-02-162,91612,547 total
  • Exercise/Conversion

    Restricted stock units

    2021-02-169220 total
    Common stock (922 underlying)
  • Exercise/Conversion

    Restricted stock units

    2021-02-148,66617,334 total
    Common stock (8,666 underlying)
Footnotes (3)
  • [F1]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F2]The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F3]The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units vest in three equal annual installments.

Documents

1 file
  • 4
    wf-form4_161359645668070.xmlPrimary

    FORM 4